Published
## Filings that contain financial statements - **Form 8-K, accession 0000310764-26-000048 (filed July 30, 2026)** — Exhibit 99.1 furnishes Stryker's second-quarter 2026 press release, which includes unaudited condensed consolidated statements of earnings, balance sheets and cash flows for the three and six months ended June 30, 2026 (with June 30, 2025 and December 31, 2025 comparatives). - **Form 8-K, accession 0000310764-26-000025 (filed April 30, 2026)** — Exhibit 99.1 furnishes the first-quarter 2026 press release, with unaudited condensed consolidated statements of earnings, balance sheets and cash flows for the three months ended March 31, 2026 (with March 31, 2025 and December 31, 2025 comparatives). - **Form 8-K, accession 0000310764-26-000006 (filed January 29, 2026)** — Exhibit 99.1 furnishes the fourth-quarter and full-year 2025 press release, with unaudited condensed consolidated statements of earnings, balance sheets and cash flows for the three months and full year ended December 31, 2025 (with 2024 comparatives). - **Form 8-K, accession 0000310764-25-000126 (filed October 30, 2025)** — Exhibit 99.1 furnishes the third-quarter 2025 press release with the same set of unaudited statements for the three and nine months ended September 30, 2025. - **Form 8-K, accession 0000310764-25-000103 (filed July 31, 2025)** — Exhibit 99.1 furnishes the second-quarter 2025 press release with unaudited statements for the three and six months ended June 30, 2025. - **Form 8-K, accession 0000310764-25-000072 (filed May 1, 2025)** — Exhibit 99.1 furnishes the first-quarter 2025 press release with unaudited statements for the three months ended March 31, 2025. - **Form 8-K, accession 0000310764-26-000041 (filed June 26, 2026)** — Exhibit 99.1 furnishes a recast of Stryker's audited full-year 2023–2025 consolidated financial statements and segment disclosures (originally reported in the 2025 Form 10-K) to reflect a first-quarter 2026 segment-reporting change; it is not a restatement of previously issued financial statements. ## Second-quarter 2026 results and guidance On July 30, 2026, Stryker reported second-quarter 2026 results (Form 8-K, accession 0000310764-26-000048): net sales of $6.6 billion, up 9.4% as reported and 9.0% organically; reported diluted EPS of $3.30 (up 44.1%); adjusted diluted EPS of $3.69 (up 17.9%). Management said the quarter reflected recovery from the cybersecurity incident disclosed earlier in the year. Stryker narrowed its full-year 2026 guidance to organic net sales growth of 8.3%–9.3% and adjusted diluted EPS of $14.95–$15.10. On April 30, 2026, Stryker reported first-quarter 2026 results (accession 0000310764-26-000025): net sales of $6.0 billion, up 2.6% as reported and 2.4% organically; reported diluted EPS of $1.93 (up 14.2%); adjusted diluted EPS of $2.60 (down 8.5%). The company maintained its full-year 2026 guidance of 8.0%–9.5% organic sales growth and adjusted diluted EPS of $14.90–$15.10. On January 29, 2026, Stryker reported fourth-quarter and full-year 2025 results and initial 2026 guidance (accession 0000310764-26-000006): full-year net sales of $25.1 billion, up 11.2%, with full-year reported diluted EPS of $8.40 and adjusted diluted EPS of $13.63. Initial 2026 guidance was for organic net sales growth of 8.0%–9.5% and adjusted diluted EPS of $14.90–$15.10. Earlier quarters: third-quarter 2025 results were reported October 30, 2025 (accession 0000310764-25-000126); second-quarter 2025 results July 31, 2025 (accession 0000310764-25-000103); first-quarter 2025 results May 1, 2025 (accession 0000310764-25-000072). ## Cybersecurity incident (March 2026) On March 11, 2026, Stryker disclosed that it had identified a cybersecurity incident affecting certain information technology systems, causing a global disruption to its Microsoft environment (Form 8-K, accession 0001193125-26-102460). At the time, the company said it had no indication of ransomware or malware and that the incident appeared contained, though the scope and financial impact were not yet known. On March 12, 2026, the company furnished a further update noting continued disruption to order processing, manufacturing and shipping, while stating patient-related services and connected products did not appear to have been affected (accession 0001193125-26-104431). On March 23, 2026, Stryker furnished a General Assurance Letter from Palo Alto Networks' Unit 42 and a customer-facing statement (accession 0001193125-26-118634). The letter stated that, as of March 20, 2026, Unit 42 had found no current evidence of active, uncontained, persistent unauthorized access, and that known indicators of compromise had been identified and addressed; the threat actor's malicious file was not capable of spreading inside or outside the company's environment, and no evidence had been found of malicious activity directed at customers, suppliers, vendors or partners. On April 9, 2026, Stryker filed Amendment No. 1 to the March 11, 2026 Form 8-K (accession 0001193125-26-149607), determining that the incident had a material impact on the company's first-quarter 2026 operating results, based on the scope and duration of the disruption and related factors. The company stated the incident was not expected to have a material impact on full-year 2026 guidance, and that it was fully operational across its global manufacturing network with commercial, ordering and distribution systems restored as of the amendment date. ## M&A Stryker's second-quarter 2026 Form 10-Q disclosures (not separately furnished by 8-K) show that in May 2026 Stryker completed the acquisition of AVS (Amplitude Vascular Systems) for net cash consideration of $435 million plus up to $400 million of future milestone payments carrying an acquisition-date fair value of $271 million, for a purchase price of $706 million net of $10 million of cash acquired. No Form 8-K in the filings reviewed through this period separately announces the AVS acquisition; it is disclosed only in the quarterly report (Form 10-Q, accession 0000310764-26-000050, for the quarter ended June 30, 2026). Stryker's prior-year acquisition of Inari Medical, Inc., completed in February 2025 for a purchase price, net of cash acquired, of approximately $4.8 billion, continues to affect reported results (e.g., elevated acquisition-and-integration costs, intangible amortization and goodwill) through the periods covered by this report, including a $139 million charge for Inari employee share-based awards that vested upon the acquisition, reflected in first-quarter 2025 results. ## Segment reporting change In the first quarter of 2026, Stryker announced a change in its organizational structure, combining the orthopaedic instruments portfolio from its Instruments business with the Mako and enabling-technologies portfolio from its Other Orthopaedics business to form a new "Ortho Tech" business. The company continues to report two segments — MedSurg and Neurotechnology, and Orthopaedics. On June 26, 2026, Stryker filed a Form 8-K (accession 0000310764-26-000041) recasting its full-year 2023–2025 consolidated financial statements and segment disclosures from the 2025 Form 10-K to reflect this change, together with a related auditor consent (Exhibit 23.1). The filing states this recast does not represent a restatement of previously issued financial statements. ## Leadership changes - **December 4, 2025** (accession 0001193125-25-308097): Stryker announced that Spencer Stiles, then Group President, Orthopaedics, was appointed President and Chief Operating Officer effective January 1, 2026, with responsibility for the company's global businesses, strategy and M&A. Dylan Crotty, then President, Instruments, was promoted to succeed Stiles as Group President, Orthopaedics, also effective January 1, 2026. - **May 20, 2026** (accession 0001193125-26-232643): Stryker announced that Vice President and Chief Accounting Officer William E. Berry, Jr. will retire effective September 1, 2026, continuing afterward in an advisory role to the CFO through August 15, 2027. Emily Baculik, then Vice President, Corporate Controller, will also become Chief Accounting Officer effective September 1, 2026. ## Annual meeting matters - **May 8, 2025** (accession 0000310764-25-000085): At Stryker's 2025 Annual Meeting, shareholders elected all ten director nominees, ratified Ernst & Young LLP as independent auditor for 2025, approved amended and restated versions of the 2011 Long-Term Incentive Plan, the 2011 Performance Incentive Award Plan and the 2008 Employee Stock Purchase Plan, and approved the advisory vote on executive compensation. - **May 6, 2026** (accession 0000310764-26-000029): At the 2026 Annual Meeting, shareholders elected all ten director nominees, ratified Ernst & Young LLP as independent auditor for 2026, and approved the advisory vote on executive compensation.